Summary
Background Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) prevents millions of clinical malaria cases in children under five in Africa’s Sahel region. However, parasites partially resistant to SP (with “quintuple” mutations) potentially threaten SMC protective effectiveness. We evaluated its spread and clinical consequences.
Methods An individual-based malaria transmission model with explicit parasite dynamics and drug pharmacological models, was used to identify and quantify the influence of factors driving quintuple mutant spread and predict the time needed for the mutant to spread from 1% to 50% of inoculations for several SMC deployment strategies. We estimated the impact of this spread on SMC effectiveness against clinical malaria.
Findings Higher transmission intensity, SMC coverage, and expanded age range of chemoprevention promoted mutant spread. SMC implementation in a high transmission setting (40% parasite prevalence in children aged 2-10 years) with four monthly cycles to children aged three months to five years (with 95% initial coverage declining each cycle), the mutant requires 53·1 years (95% CI 50·5–56·0) to spread from 1% to 50% of inoculations. This time increased in lower transmission settings and reduced by half when SMC was extended to children under ten, or reduced by 10-13 years when an additional monthly cycle of SMC was deployed. For the same setting, the effective reduction in clinical cases in children receiving SMC was 79·0% (95% CI 77·8–80·8) and 60·4% (95% CI 58·6–62·3) during the months of SMC implementation when the mutant was absent or fixed in the population, respectively.
Interpretation SMC with SP+AQ leads to a relatively slow spread of SP-resistant quintuple mutants and remains effective at preventing clinical malaria despite the mutant spread. SMC with SP+AQ should be considered in seasonal settings where this mutant is already prevalent.
Funding Swiss National Science Foundation and Marie Curie Individual Fellowship.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded through a Swiss National Science Foundation Professorship grant of MAP (P00P3_170702). TL was funded through a Marie Curie Individual Fellowship (839121, Horizon 2020).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Individual participant-level data was not used in this study. Parameter values used to inform the model were extracted from the literature as described in the main text or in the appendix. All data and code used to produce the figures are available at https://zenodo.org/record/7244708. In addition, the code used to run the simulations and perform the analyses can be found at https://zenodo.org/record/7244732. The individual-based model of malaria transmission and epidemiology used in the study has an open-access code (https://github.com/SwissTPH/openmalaria) and documentation (https://github.com/SwissTPH/openmalaria/wiki).